Ruxolitinib continues to demonstrate its effectiveness in treating chronic graft-versus-host disease (cGVHD), according to updated data from the REACH3 trial. The findings, reviewed by Stephanie Lee, MD, MPH, underscore the drug's significant impact on patients with steroid-refractory or steroid-dependent cGVHD.
The REACH3 trial is a phase 3, randomized, open-label study evaluating ruxolitinib versus best available therapy (BAT) in patients with steroid-refractory or steroid-dependent chronic GVHD after allogeneic hematopoietic stem cell transplantation. The primary endpoint was overall response rate (ORR) at week 24. Key secondary endpoints included failure-free survival (FFS) and changes in Lee Symptom Scale (LSS) score.
Key Findings from REACH3
Dr. Lee highlighted that the updated data reinforce ruxolitinib's role in managing cGVHD. The trial's results demonstrated a statistically significant improvement in ORR at week 24 with ruxolitinib compared to BAT. Furthermore, ruxolitinib showed a trend towards improved FFS and meaningful reductions in symptom burden as measured by the LSS.
Clinical Implications
The REACH3 trial's findings have significant implications for treatment planning in cGVHD. Molecular testing and comprehensive assessment of patient-specific factors are crucial in determining the most appropriate therapeutic strategy. Ruxolitinib offers a valuable option for patients who have not responded adequately to steroid therapy, addressing a critical unmet need in this population.
Expert Commentary
In an interview with Targeted Oncology, Dr. Lee emphasized the importance of these results for the broader cGVHD population. "The REACH3 trial provides compelling evidence supporting the use of ruxolitinib in patients with chronic GVHD who have failed steroid treatment," she stated. "These data help inform clinical decision-making and improve outcomes for patients facing this challenging condition."
